Quality of life with talazoparib versus physicianʼs choice of chemotherapy in patients with advanced breast cancer and germline BRCA1/2 mutation: patient-reported outcomes from the EMBRACA phase III trial - Ettl, J; Quek, R; Lee, K-H (Ann Oncol, 2018)